| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/31/2013 | US20130028956 Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore |
| 01/31/2013 | US20130028941 Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
| 01/31/2013 | US20130028936 Tlr 4 and 9 receptors agonists for preventing septic complications of post-traumatic immunodepression in patients hospitalized for severe traumatic injuries |
| 01/31/2013 | US20130028935 Composition containing hcmv particles |
| 01/31/2013 | US20130028934 Stabilizer and Vaccine Composition Comprising One or More Live Attenuated Flaviviruses |
| 01/31/2013 | US20130028933 Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions |
| 01/31/2013 | US20130028932 Compositions comprising polyglutamic acid nanoparticles and polypeptides such as cd40 agonists |
| 01/31/2013 | US20130028931 Novel prrs virus inducing type i interferon in susceptible cells |
| 01/31/2013 | US20130028930 Albumin Derivatives and Variants |
| 01/31/2013 | US20130028928 Methods to increase antigenicity of membrane bound polypeptides produced in plants |
| 01/31/2013 | US20130028927 Method of diagnosing and treating melioidosis |
| 01/31/2013 | US20130028926 Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| 01/31/2013 | US20130028925 Herpes simplex virus combined subunit vaccines and methods of use thereof |
| 01/31/2013 | US20130028924 Constructs for enhancing immune responses |
| 01/31/2013 | US20130028923 Kdr peptides and vaccines comprising the same |
| 01/31/2013 | US20130028922 Citrulline peptides derived from fibrin and recognized by rheumatoid arthritis specific autoantibodies, and the use thereof |
| 01/31/2013 | US20130028921 Composition comprising coumestrol or a bean extract containing coumestrol |
| 01/31/2013 | US20130028920 Stabilized antibody preparations and uses thereof |
| 01/31/2013 | US20130028919 Targeted pyrrolobenzodiazapine conjugates |
| 01/31/2013 | US20130028918 Insulin conjugate using an immunoglobulin fragment |
| 01/31/2013 | US20130028917 Pyrrolobenzodiazepines and conjugates thereof |
| 01/31/2013 | US20130028916 Antagonist anti-il-7 receptor antibodies and methods |
| 01/31/2013 | US20130028915 Dendritic cell (dc)-vaccine therapy for pancreatic cancer |
| 01/31/2013 | US20130028914 Antibodies that Bind Tau Oligomers |
| 01/31/2013 | US20130028913 Antibody that binds to h-1 parvovirus |
| 01/31/2013 | US20130028912 Tweak/fn14 system regulates skeletal muscle atrophy and regeneration |
| 01/31/2013 | US20130028911 Vascular endothelial cell growth factor antagonists |
| 01/31/2013 | US20130028910 Hmg1 antibody for treating inflammatory conditions |
| 01/31/2013 | US20130028909 Depletion of Teratoma-Forming Pluripotent Stem Cells |
| 01/31/2013 | US20130028908 MONOCLONAL ANTIBODIES DIRECTED AGAINST HIV p17 PROTEIN |
| 01/31/2013 | US20130028907 Stable Antibody Containing Compositions |
| 01/31/2013 | US20130028906 Human antibodies that bind mesothelin, and uses thereof |
| 01/31/2013 | US20130028905 Human antibodies that bind mesothelin, and uses thereof |
| 01/31/2013 | US20130028904 Human antibodies that bind mesothelin, and uses thereof |
| 01/31/2013 | US20130028903 Purified antibody composition |
| 01/31/2013 | US20130028902 Osteocalcin as a treatment for male reproductive disorders |
| 01/31/2013 | US20130028901 Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| 01/31/2013 | US20130028900 Methods and compositions for the generation and use of conformation-specific antibodies |
| 01/31/2013 | US20130028899 Treatment of cancer by inhibiting activity or expression of late sv-40 factor |
| 01/31/2013 | US20130028898 Combination therapy with cd4 lymphocyte depletion and mtor inhibitors |
| 01/31/2013 | US20130028897 Methods for reducing the level of alloantibodies in a subject |
| 01/31/2013 | US20130028896 Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses |
| 01/31/2013 | US20130028895 Exosome inhibiting agents and uses thereof |
| 01/31/2013 | US20130028894 Methods of treating il-tif associated inflammatory or immune diseases using antibodies against soluble zcytor 11 cytokine receptors |
| 01/31/2013 | US20130028893 Therapeutic antibodies with reduced side effect |
| 01/31/2013 | US20130028892 Method of treating osteoarthritis with an antibody to ngf |
| 01/31/2013 | US20130028891 Unconjugated Anti-TfR Antibodies and Compositions Thereof for the Treatment of Cancer |
| 01/31/2013 | US20130028890 Method for detecting regulatory t cells using expression of folate receptor 4 as indicator, method for treating diseases using the detection method, pharmaceutical composition for immunostimulation, and method for treating diseases using the composition |
| 01/31/2013 | US20130028889 Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
| 01/31/2013 | US20130028888 Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 01/31/2013 | US20130028887 Phenylacetic acid compound |
| 01/31/2013 | US20130028886 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells |
| 01/31/2013 | US20130028885 Methods to predict and prevent resistance to taxoid compounds |
| 01/31/2013 | US20130028862 Treatment with anti-vegf antibodies |
| 01/31/2013 | US20130028860 Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue and/or fever |
| 01/31/2013 | US20130028857 Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
| 01/31/2013 | US20130028850 Topical tetracycline compositions |
| 01/31/2013 | US20130028836 Chlorotoxin polypeptides and conjugates and uses thereof |
| 01/31/2013 | US20130028835 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses |
| 01/31/2013 | CA2843200A1 Dendritic cell (dc)-vaccine therapy for pancreatic cancer |
| 01/31/2013 | CA2843182A1 Novel salmonella bacteriophage compositions and uses thereof |
| 01/31/2013 | CA2842796A1 Tumor selective chemokine modulation |
| 01/31/2013 | CA2842626A1 Methods and compositions for vaccinating against staphylococcus aureus |
| 01/31/2013 | CA2842443A1 Synthetic lethality and the treatment of cancer |
| 01/31/2013 | CA2841588A1 Stabilized formulations containing anti-pcsk9 antibodies |
| 01/31/2013 | CA2841380A1 Prame purification |
| 01/31/2013 | CA2841036A1 Compositions having means for targeting at least one antigen to dendritic cells |
| 01/31/2013 | CA2840018A1 Variants of humanized immunomodulatory monoclonal antibodies |
| 01/30/2013 | EP2551347A1 Pharmaceutical composition for preventing or treating cancer |
| 01/30/2013 | EP2551345A1 Hcv variant with high productivity of infectious hepatitis c virus, and use thereof |
| 01/30/2013 | EP2551282A2 Antibodies against CD38 for treatment of multiple myeloma |
| 01/30/2013 | EP2550975A1 Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
| 01/30/2013 | EP2550974A2 Universal influenza vaccine based on recombinant modified vaccinia Ankara virus (MVA) |
| 01/30/2013 | EP2550870A1 Novel salmonella bacteriophage compositions and uses thereof |
| 01/30/2013 | EP2550362A2 Cmv glycoproteins and recombinant vectors |
| 01/30/2013 | EP2550361A1 Compositions and methods for treating neurological disorders |
| 01/30/2013 | EP2550298A2 Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| 01/30/2013 | EP2550295A1 Anti-lrp6 antibodies |
| 01/30/2013 | EP2550294A2 Prophylaxis of colorectal and gastrointestinal cancer |
| 01/30/2013 | EP2550292A2 Flavivirus host range mutations and uses thereof |
| 01/30/2013 | EP2550289A2 Novel immunogens and methods for discovery and screening thereof |
| 01/30/2013 | EP2550019A2 Temperature sensitive conjugate compositions, and uses related thereto |
| 01/30/2013 | EP2550018A1 Compositions and methods useful for stabilizing protein-containing formulations |
| 01/30/2013 | EP2550017A2 Disulfide stabilised antibodies and fragments thereof |
| 01/30/2013 | EP2550016A2 Adjuvant diluents for live vaccines for pig diseases |
| 01/30/2013 | EP2550015A1 Live vaccine for aviary diseases |
| 01/30/2013 | EP2550014A1 Papillomavirus virus-like particle or capsomere formulation and its use as microbicide |
| 01/30/2013 | EP2550013A1 Treating allergy with detoxified e. coli heat-labile enterotoxin |
| 01/30/2013 | EP2550012A1 Phage constructs, sequences and antigenic compositions for immunocontraception of animals |
| 01/30/2013 | EP2550011A1 Use of pcsk9 as a vaccine for lowering cholesterol |
| 01/30/2013 | EP2550010A1 Method and compositions to induce apoptosis of tumoral cells expressing shh |
| 01/30/2013 | CN102906266A Universal dengue virus sequences and methods of use |
| 01/30/2013 | CN102906249A Induced malignant stem cells or pre-induction cancer stem cells capable of self-replication outside of an organism, production method for same, and practical application for same |
| 01/30/2013 | CN102906245A Hyperblebbing shigella strains |
| 01/30/2013 | CN102906118A Biological materials related to HER3 |
| 01/30/2013 | CN102906117A Anti-LRP6 antibodies |
| 01/30/2013 | CN102906111A Human antibodies specifically binding to the hepatitis B virus surface antigen |
| 01/30/2013 | CN102905730A Zwitterionic polymer bioconjugates and related methods |
| 01/30/2013 | CN102905727A IL-17A antagonists |
| 01/30/2013 | CN102905726A Oral vaccine comprising antigen and Toll-like receptor agonist |